Stokes Family Office’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-8,599
| Closed | -$1.29M | – | 238 |
|
|
2025
Q1 | $1.29M | Buy |
8,599
+990
| +13% | +$149K | 0.15% | 110 |
|
|
2024
Q4 | $1.4M | Sell |
7,609
-2,190
| -22% | -$404K | 0.15% | 101 |
|
|
2024
Q3 | $1.93M | Buy |
9,799
+1,465
| +18% | +$289K | 0.21% | 84 |
|
|
2024
Q2 | $1.72M | Buy |
8,334
+1,400
| +20% | +$289K | 0.2% | 89 |
|
|
2024
Q1 | $1.88M | Buy |
6,934
+1,840
| +36% | +$499K | 0.23% | 86 |
|
|
2023
Q4 | $1.2M | Buy |
5,094
+659
| +15% | +$156K | 0.16% | 101 |
|
|
2023
Q3 | $869K | Buy |
+4,435
| New | +$869K | 0.1% | 140 |
|